These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28824834)

  • 1. Methodologic Issues When Estimating Risks in Pharmacoepidemiology.
    Edwards JK; Hester LL; Gokhale M; Lesko CR
    Curr Epidemiol Rep; 2016 Dec; 3(4):285-296. PubMed ID: 28824834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.
    de Glas NA; Kiderlen M; Vandenbroucke JP; de Craen AJ; Portielje JE; van de Velde CJ; Liefers GJ; Bastiaannet E; Le Cessie S
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26614095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of disease-risk score in pharmacoepidemiologic studies].
    Zhao HY; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):261-266. PubMed ID: 28231678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bias Due to Confounders for the Exposure-Competing Risk Relationship.
    Lesko CR; Lau B
    Epidemiology; 2017 Jan; 28(1):20-27. PubMed ID: 27748680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for analysis of time-to-event outcomes subject to competing risks in veterinary clinical studies.
    Oyama MA; Shaw PA; Ellenberg SS
    J Vet Cardiol; 2018 Jun; 20(3):143-153. PubMed ID: 29680637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction to the Analysis of Survival Data in the Presence of Competing Risks.
    Austin PC; Lee DS; Fine JP
    Circulation; 2016 Feb; 133(6):601-9. PubMed ID: 26858290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications.
    Varadhan R; Weiss CO; Segal JB; Wu AW; Scharfstein D; Boyd C
    Med Care; 2010 Jun; 48(6 Suppl):S96-105. PubMed ID: 20473207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A note on competing risks in survival data analysis.
    Satagopan JM; Ben-Porat L; Berwick M; Robson M; Kutler D; Auerbach AD
    Br J Cancer; 2004 Oct; 91(7):1229-35. PubMed ID: 15305188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the application of spatial analysis in pharmacoepidemiologic research.
    Dijkstra A; Hak E; Janssen F
    Ann Epidemiol; 2013 Aug; 23(8):504-14. PubMed ID: 23830932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative incidence in competing risks data and competing risks regression analysis.
    Kim HT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
    Etminan M; Gill S; Fitzgerald M; Samii A
    J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count.
    Dong H; Robison LL; Leisenring WM; Martin LJ; Armstrong GT; Yasui Y
    Am J Epidemiol; 2015 Apr; 181(7):532-40. PubMed ID: 25693770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoepidemiology in Pharmacogenetics.
    Ahern TP
    Adv Pharmacol; 2018; 83():109-130. PubMed ID: 29801572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invited commentary: Estimating population impact in the presence of competing events.
    Naimi AI; Tchetgen Tchetgen EJ
    Am J Epidemiol; 2015 Apr; 181(8):571-4. PubMed ID: 25816819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative incidence rate of medical consultation for fecundity problems--analysis of a prevalent cohort using competing risks.
    Duron S; Slama R; Ducot B; Bohet A; Sørensen DN; Keiding N; Moreau C; Bouyer J
    Hum Reprod; 2013 Oct; 28(10):2872-9. PubMed ID: 23838160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An empirical assessment of immeasurable time bias in the setting of nested case-control studies: Statins and all-cause mortality among patients with heart failure.
    Oh IS; Filion KB; Jeong HE; Shin JY
    Pharmacoepidemiol Drug Saf; 2019 Oct; 28(10):1318-1327. PubMed ID: 31432599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse probability of treatment-weighted competing risks analysis: an application on long-term risk of urinary adverse events after prostate cancer treatments.
    Bolch CA; Chu H; Jarosek S; Cole SR; Elliott S; Virnig B
    BMC Med Res Methodol; 2017 Jul; 17(1):93. PubMed ID: 28693428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplant as a competing risk in the analysis of dialysis patients.
    van Geloven N; le Cessie S; Dekker FW; Putter H
    Nephrol Dial Transplant; 2017 Apr; 32(suppl_2):ii53-ii59. PubMed ID: 28340227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of competing risks analysis improved prognostic assessment of patients with decompensated chronic heart failure and reduced left ventricular ejection fraction.
    Scrutinio D; Guida P; Passantino A; Ammirati E; Oliva F; Lagioia R; Frigerio M
    J Clin Epidemiol; 2018 Nov; 103():31-39. PubMed ID: 30009940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.